ReSynapse Therapeutics

Novel Multi-Target Neuropsychiatric Drugs via Computational Drug Design

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in December 2024 by Dorit Cohen Carmon, ReSynapse Therapeutics operates with 1–10 employees. The company has secured two funding rounds, including a Pre-Seed round in May 2025, to advance its computational drug design platform.

Business overview

ReSynapse Therapeutics is a biotechnology company focused on developing selective multi-target small molecules for treatment-resistant depression. The company utilizes a systematic computational drug design approach to identify compounds that precisely modulate multiple serotonin receptors simultaneously. This methodology combines validated receptor biology with proprietary computational techniques to enhance efficacy and safety, serving the health tech and life sciences sectors, particularly in drug discovery and development for pharmaceuticals.

Company Intelligence Q&A

When was ReSynapse Therapeutics founded?: ReSynapse Therapeutics was founded in December 2024.
Who is the founder of ReSynapse Therapeutics?: The company was founded by Dorit Cohen Carmon.
What is ReSynapse Therapeutics' primary focus?: ReSynapse Therapeutics focuses on developing novel multi-target neuropsychiatric drugs using computational drug design, specifically targeting treatment-resistant depression.
What is ReSynapse Therapeutics' current stage of product development?: ReSynapse Therapeutics is currently in the R&D stage, with in-vitro POC validation in progress and plans for IP filing in Q1 2026.
What is the company's approach to drug design?: ReSynapse Therapeutics designs single molecules that modulate specific combinations of serotonin receptors using mechanism-based computational chemistry, integrating structural biology and pharmacological understanding.

External links

ReSynapse Therapeutics — full profile (machine-readable)

ReSynapse Therapeutics is a biotechnology company developing selective multi-target small molecules for treatment-resistant depression. Using systematic computational drug design, we identify compounds that precisely modulate multiple serotonin receptors simultaneously. Our approach combines validated receptor biology with proprietary computational methodologies for better efficacy and safety. The Challenge 20-30% of depression and anxiety patients are treatment-resistant, achieving only 16.7% remission rates with current therapies. Single-target approaches (SSRIs, SNRIs) require 4-6 weeks with significant side effects. Psychedelic-based treatments face regulatory challenges (FDA rejected Lykos' MDMA therapy August 2024). Our Approach We design single molecules that modulate specific combinations of serotonin receptors using mechanism-based computational chemistry. Our platform integrates structural biology, pharmacological understanding, and validated receptor targets to design multi-target compounds systematically. Differentiation • Validated receptor biology (4 specific receptors, 25+ study meta-analysis) eliminates target risk • Proprietary computational methodologies enable systematic multi-target design, impossible with standard software • Selective serotonin targeting avoids dopamine/adrenergic side effects of existing multi-target drugs Current Progress • A combination of 4 receptors was identified and validated for depression • 39 receptor structures systematically analyzed • Various drug candidates identified • In-vitro POC validation is in progress • Non-dilutive grants secured (competitive peer review validation) • IP filing: Q1 2026 | POC validation: Q3-Q4 2026 Stage Seed fundraising for POC validation, lead optimization, and preclinical development pathway. Market Treatment-resistant depression: $1.9B market (2.8M Americans, 11M Europeans). Platform of multi-target drugs is scalable to anxiety, PTSD, other CNS indications.

Facts
Name	ReSynapse Therapeutics
One-liner	Novel Multi-Target Neuropsychiatric Drugs via Computational Drug Design
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2024
Employees	1-10
Employees (exact)	2
HQ / location	Ness Ziona, Ness Ziona, Israel, Center District
Product stage	R&D
Website	https://resynapse.carrd.co/
LinkedIn	https://www.linkedin.com/company/resynapse-therapeutics/
IL Registrar	517161493

Facts

Name

ReSynapse Therapeutics

One-liner

Novel Multi-Target Neuropsychiatric Drugs via Computational Drug Design

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2024

Employees

1-10

Employees (exact)

HQ / location

Ness Ziona, Ness Ziona, Israel, Center District

Product stage

R&D

Website

https://resynapse.carrd.co/

https://www.linkedin.com/company/resynapse-therapeutics/

IL Registrar

517161493

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development
Core technology	Platforms & Interfaces
Target customers	Healthcare & Life Sciences, Life Sciences, Pharmaceuticals
Business models	B2B, B2C, B2B2C
Tags	psychiatry, mental-health, drug-development, data-science-platform, drug-design, neuroscience, biotechnology, oral-drugs, drug-discovery, precision-medicine

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development

Core technology

Platforms & Interfaces

Target customers

Healthcare & Life Sciences, Life Sciences, Pharmaceuticals

Business models

B2B, B2C, B2B2C

Date	Round	Amount	Investors
May 2025	Pre-Seed	Undisclosed
	nonequity	Undisclosed

ReSynapse Therapeutics

Company Overview

Snapshot

Business overview

Company Intelligence Q&A

External links

Generate Slim Page